The clinical limitations of IFN-α therapy in established infection reflect several fundamental barriers, including cumulative toxicity from sustained exposure, reinforcement of immune exhaustion, failure to eradicate the latent reservoir, and viral antagonism of interferon signaling. This evidence concerns the gene IFNA1 and infection.